PROPHASE LABS INC (PRPH)
US74345W1080 - Common Stock
Taking everything into account, PRPH scores 3 out of 10 in our fundamental rating. PRPH was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRPH have multiple concerns. PRPH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
PRPH had negative earnings in the past year.
PRPH had a negative operating cash flow in the past year.
In multiple years PRPH reported negative net income over the last 5 years.
PRPH had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -28.08%, PRPH is in line with its industry, outperforming 56.77% of the companies in the same industry.
PRPH has a Return On Equity of -59.69%. This is comparable to the rest of the industry: PRPH outperforms 50.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -59.69% | ||
| ROIC | N/A |
ROA(3y)3.3%
ROA(5y)-4.41%
ROE(3y)1.95%
ROE(5y)-8.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRPH has been increased compared to 1 year ago.
Compared to 5 years ago, PRPH has more shares outstanding
PRPH has a worse debt/assets ratio than last year.
2.2 Solvency
PRPH has an Altman-Z score of -0.83. This is a bad value and indicates that PRPH is not financially healthy and even has some risk of bankruptcy.
PRPH has a Altman-Z score of -0.83. This is comparable to the rest of the industry: PRPH outperforms 46.88% of its industry peers.
PRPH has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
PRPH has a Debt to Equity ratio of 0.24. This is comparable to the rest of the industry: PRPH outperforms 41.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.83 |
ROIC/WACCN/A
WACC10.68%
2.3 Liquidity
PRPH has a Current Ratio of 1.58. This is a normal value and indicates that PRPH is financially healthy and should not expect problems in meeting its short term obligations.
PRPH has a Current ratio of 1.58. This is in the lower half of the industry: PRPH underperforms 72.40% of its industry peers.
A Quick Ratio of 1.44 indicates that PRPH should not have too much problems paying its short term obligations.
PRPH has a worse Quick ratio (1.44) than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for PRPH have decreased strongly by -113.56% in the last year.
The Revenue for PRPH has decreased by -63.80% in the past year. This is quite bad
The Revenue has been growing by 27.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-113.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-63.8%
Revenue growth 3Y45.2%
Revenue growth 5Y27.64%
Sales Q2Q%-62.34%
3.2 Future
Based on estimates for the next years, PRPH will show a very strong growth in Earnings Per Share. The EPS will grow by 58.10% on average per year.
PRPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.73% yearly.
EPS Next Y36.51%
EPS Next 2Y58.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.53%
Revenue Next 2Y63.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRPH. In the last year negative earnings were reported.
PRPH is valuated cheaply with a Price/Forward Earnings ratio of 1.57.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PRPH indicates a rather cheap valuation: PRPH is cheaper than 99.48% of the companies listed in the same industry.
PRPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.00, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.57 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PRPH's earnings are expected to grow with 58.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.1%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for PRPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROPHASE LABS INC
NASDAQ:PRPH (11/22/2024, 8:00:00 PM)
After market: 0.7503 -0.02 (-2.42%)0.7689
-0.01 (-1.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap18.35M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.57 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -59.69% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-113.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y36.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-63.8%
Revenue growth 3Y45.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y